Oxford BioDynamics Plc (OXBOF)
USD 0.02
(-86.0%)
USD 0.02
(-86.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -11.02 Million GBP | -28.19% |
| 2022 | -8.6 Million GBP | -14.5% |
| 2021 | -7.51 Million GBP | -51.73% |
| 2020 | -4.95 Million GBP | -32.98% |
| 2019 | -3.72 Million GBP | -43.08% |
| 2018 | -2.6 Million GBP | 35.0% |
| 2017 | -4 Million GBP | -71.95% |
| 2016 | -2.32 Million GBP | -87.29% |
| 2015 | -1.24 Million GBP | -62.48% |
| 2014 | -765 Thousand GBP | 29.75% |
| 2013 | -1.08 Million GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.99 Million GBP | 0.0% |
| 2024 Q1 | -2.99 Million GBP | 50.36% |
| 2023 Q2 | -4.95 Million GBP | -108.41% |
| 2023 Q1 | -2.37 Million GBP | 49.01% |
| 2023 Q4 | -6.03 Million GBP | -123.18% |
| 2023 Q3 | -2.7 Million GBP | 45.44% |
| 2023 FY | -11.02 Million GBP | -28.19% |
| 2022 Q3 | -2.24 Million GBP | 47.68% |
| 2022 FY | -8.6 Million GBP | -14.5% |
| 2022 Q1 | -2.05 Million GBP | 49.29% |
| 2022 Q2 | -4.28 Million GBP | -108.26% |
| 2022 Q4 | -4.66 Million GBP | -108.07% |
| 2021 Q4 | -4.05 Million GBP | -100.05% |
| 2021 Q2 | -3.45 Million GBP | -100.06% |
| 2021 Q1 | -1.72 Million GBP | 33.43% |
| 2021 FY | -7.51 Million GBP | -51.73% |
| 2021 Q3 | -2.02 Million GBP | 41.3% |
| 2020 FY | -4.95 Million GBP | -32.98% |
| 2020 Q2 | -2.35 Million GBP | -100.08% |
| 2020 Q3 | -1.29 Million GBP | 45.04% |
| 2020 Q1 | -1.17 Million GBP | 43.37% |
| 2020 Q4 | -2.59 Million GBP | -100.15% |
| 2019 FY | -3.72 Million GBP | -43.08% |
| 2019 Q1 | -839.5 Thousand GBP | -27.49% |
| 2019 Q4 | -2.08 Million GBP | -103.72% |
| 2019 Q2 | -839.5 Thousand GBP | 0.0% |
| 2019 Q3 | -1.02 Million GBP | -21.74% |
| 2018 FY | -2.6 Million GBP | 35.0% |
| 2018 Q1 | -642.5 Thousand GBP | -6.91% |
| 2018 Q2 | -642.5 Thousand GBP | 0.0% |
| 2018 Q3 | -658.5 Thousand GBP | -2.49% |
| 2018 Q4 | -658.5 Thousand GBP | 0.0% |
| 2017 Q3 | -601 Thousand GBP | 8.31% |
| 2017 FY | -4 Million GBP | -71.95% |
| 2017 Q4 | -601 Thousand GBP | 0.0% |
| 2017 Q2 | -655.5 Thousand GBP | 0.0% |
| 2017 Q1 | -655.5 Thousand GBP | -64.7% |
| 2016 Q1 | -542.5 Thousand GBP | -9.26% |
| 2016 Q2 | -542.5 Thousand GBP | 0.0% |
| 2016 Q4 | -398 Thousand GBP | 0.0% |
| 2016 FY | -2.32 Million GBP | -87.29% |
| 2016 Q3 | -398 Thousand GBP | 26.64% |
| 2015 Q4 | -496.5 Thousand GBP | 0.0% |
| 2015 Q3 | -496.5 Thousand GBP | -61.46% |
| 2015 FY | -1.24 Million GBP | -62.48% |
| 2015 Q1 | -307.5 Thousand GBP | 0.0% |
| 2015 Q2 | -307.5 Thousand GBP | 0.0% |
| 2014 FY | -765 Thousand GBP | 29.75% |
| 2013 FY | -1.08 Million GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -188.628% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 84.64% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -4112.803% |
| SQZ Biotechnologies Company | -75.82 Million USD | 85.459% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -286.808% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 38.219% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 113.471% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -617.816% |
| Marizyme, Inc. | -34.08 Million USD | 67.653% |
| Genus plc | 6.4 Million USD | 272.281% |
| Pharming Group N.V. | -4.87 Million USD | -125.964% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -455.052% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1083.835% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -32.048% |
| ContraFect Corporation | -56.88 Million USD | 80.618% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -686.453% |
| IMV Inc. | -38.67 Million USD | 71.488% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -300.823% |
| ONE Bio Corp. | 13.68 Million USD | 180.59% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 81.309% |
| Mesoblast Limited | -84.14 Million USD | 86.897% |
| MultiCell Technologies, Inc. | -722.81 USD | -1525335.453% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 411.469% |
| Genscript Biotech Corporation | -415.79 Million USD | 97.348% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -2730.3% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -319.635% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 324.342% |
| Biomind Labs Inc. | -1 Million USD | -992.112% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -280.043% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -65.854% |
| Skye Bioscience, Inc. | -13.67 Million USD | 19.352% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -491.406% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 213.175% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -36712.233% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -142.078% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -118.575% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 30.522% |
| Accustem Sciences Inc. | -3.74 Million USD | -194.308% |
| EV Biologics, Inc. | -483.06 Thousand USD | -2182.523% |
| Q BioMed Inc. | -3.44 Million USD | -220.001% |
| GB Sciences, Inc. | -1.42 Million USD | -676.201% |
| Alpha Cognition Inc. | -9.7 Million USD | -13.605% |
| CSL Limited | 3.7 Billion USD | 100.298% |
| Agentix Corp. | -1.37 Million USD | -703.787% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 79.943% |
| Enzolytics Inc. | -2.14 Million USD | -413.124% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 13.515% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -248.013% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -470.524% |
| argenx SE | -425.04 Million USD | 97.406% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 80.136% |
| HST Global, Inc. | -140.9 Thousand USD | -7725.019% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -956.13% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -880.171% |
| Halberd Corporation | -75.05 Thousand USD | -14591.539% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -277.675% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -223.82% |
| Zenith Capital Corp. | -8.94 Million USD | -23.292% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -598.133% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -349.066% |
| AVAX Technologies, Inc. | 6.69 Million USD | 264.742% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -6328.797% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -449.992% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -63191.43% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -346.983% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1020.468% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -777.866% |
| Kadimastem Ltd | -3.04 Million USD | -262.668% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -41.741% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -5975.433% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -725.651% |
| LadRx Corporation | -3.82 Million USD | -188.365% |
| Cell Source, Inc. | -4.32 Million USD | -154.916% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2553.804% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1505.066% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1505.066% |
| Affymax, Inc. | -15.04 Million USD | 26.718% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1888.279% |
| Itoco Inc. | -919.14 Thousand USD | -1099.6% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -160.144% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -885.344% |
| International Stem Cell Corporation | -663 Thousand USD | -1563.047% |
| CytoDyn Inc. | -18.05 Million USD | 38.941% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -43706.118% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -4910.042% |
| Qrons Inc. | -643.67 Thousand USD | -1612.971% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1852.462% |
| SYBLEU INC | -149.18 Thousand USD | -7291.071% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -394.466% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1560.542% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -507.052% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -20846.049% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -54108.456% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 69.597% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -581.459% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1398.434% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -254.42% |
| Neutra Corp. | -229.48 Thousand USD | -4704.65% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 37.134% |
| PureTech Health plc | -146.19 Million USD | 92.458% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 48.695% |
| IXICO plc | -1.43 Million USD | -667.293% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -16.173% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 90.948% |
| CSL Limited | 3.81 Billion USD | 100.289% |
| Cellectis S.A. | -108.85 Million USD | 89.871% |